Skip to main content

Market Overview

Top 3 Health Care Stocks That May Explode In Q4

Share:
Top 3 Health Care Stocks That May Explode In Q4

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

Silence Therapeutics PLC – ADR (NASDAQ:SLN)

  • On Dec. 10, Chardan Capital analyst Keay Nakae maintained Silence Therapeutics with a Buy and maintained a $55 price target. The company's stock fell around 41% over the past month and has a 52-week low of $5.81.
  • RSI Value: 26.72                        
  • SLN Price Action: Shares of Silence Therapeutics fell 3.4% to close at $6.51 on Tuesday.
  • Benzinga Pro's real-time newsfeed alerted to latest SLN news.

ModivCare Inc (NASDAQ:MODV)         

  • On Nov. 6, ModivCare posted weaker-than-expected quarterly results. “This quarter has demonstrated positive momentum, reflected in both operational enhancements and strengthened relationships, even amid shifts in the broader healthcare market. We delivered solid third-quarter results, reporting $43 million of adjusted EBITDA and a 2% increase in consolidated revenue, driven primarily by 5% growth in our personal care services segment,” stated L. Heath Sampson, President and CEO. The company's stock fell around 26% over the past five days and has a 52-week low of $11.00.
  • RSI Value: 28.52
  • MODV Price Action: Shares of ModivCare fell 11.4% to close at $14.10 on Tuesday.
  • Benzinga Pro’s charting tool helped identify the trend in MODV stock.

Olema Pharmaceuticals Inc (NASDAQ:OLMA)

  • On Dec. 10, Olema Oncology presented updated clinical results for Palazestrant in combination with Ribociclib at the San Antonio Breast Cancer Symposium. The company's stock fell around 37% over the past five days and has a 52-week low of $6.08.
  • RSI Value: 23.69
  • OLMA Price Action: Shares of Olema Pharmaceuticals fell 4.7% to close at $6.14 on Tuesday.
  • Benzinga Pro’s signals feature notified of a potential breakout in OLMA shares.

Read This Next:

 

Related Articles (OLMA + MODV)

View Comments and Join the Discussion!

Posted-In: Expert Ideas health care OVERSOLDLong Ideas News Pre-Market Outlook Markets Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com